MEGIN (formerly Elekta Oy), a Stockholm, Sweden-based provider of magnetoencephalography (MEG) technology, announces Arkansas Children’s Hospital has signed an agreement to purchase from the company a “TRIUX neo” MEG system for functional brain imaging.
MEG is a completely non-invasive diagnostic device and directly measures magnetic activity generated by neurons in the brain. TRIUX neo is being used in the diagnosis and assessment of complex neurological disruptions and is able to detect and localize neural events with millimeter accuracy and with millisecond resolution. This detection capability is impactful when diagnosing patients across a wide spectrum of conditions, including epilepsy, brain tumors, traumatic brain injury, post-traumatic stress disorder, and autism.
“MEG is a state-of-the-art device that can precisely localize the source of seizures within the brain to help provide a life-changing cure for select children with uncontrolled epilepsy,” says Gregory Sharp, MD, chief of neurology at Arkansas Children’s Hospital, the state’s only pediatric health system. “This asset will lead to new understandings of neurologic disorders through research.”
“We are very excited to be working with Arkansas Children’s Hospital and providing our latest technology in functional brain imaging for their patients,” says Janne Huhtala, CEO of MEGIN. “The information gained through the use of MEG can have a significant impact on patients who are otherwise left with few definitive answers when faced with surgery.”
The TRIUX neo system is scheduled to be installed at Arkansas Children’s Hospital by the end of the year.